An Overview of the Regulatory Landscape Relevant to Tissue and Cell Based Therapies within the EU, Considering Both Adult and Embryonic Stem Cells

Posted by

SELECTBIO

Julian Hitchcock, Counsel, Lawford Davies Denoon

Abstract
Regulation is cited as the biggest obstacle to investment in regenerative medicine and stem cell science. In this talk, Julian Hitchcock sets out the European legal framework standing between research output and clinical implementation, highlighting some topical issues on the way.